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Aims: To prospectively assess the prevalence of Exophiala dermatitidis (ED) in
respiratory secretions of patients with CF and to identify risk factors for its presence.
Methods: The results of all cultures performed over a 2 years period in non
lung-transplanted patients were considered. To detect fungi, cultures were grown
on Sabouraud Gentamicin-Chloramphenicol Agar medium (Becton-Dickinson) and
incubated at 35ºC for 2 days and then at ambient temperature (15−25ºC) for 3 weeks.
Group A included all patients with one or more sputum cultures + for ED, Group B
ED− patients 12 y.
Results: The study group included 154 patients (76M, 48% >18 y, median number
of cultures/patient/2 years: 12). Out of 2.065 cultures, ED was isolated from 58
specimens (2.8%), in 9 patients (5.8%). All ED+ patients were PI and 12 y of
age. Comparison of Groups A and B (n = 90) revealed that isolation of Aspergillus
fumigatus at the last culture of the study period was more frequent in patients from
Group A (44.4 % vs 10%, p = 0.017). A larger proportion of patients homozygous
for the F508 del mutation was also observed in this group (88.9% vs 48.9%,
p = 0.052). There was no signiﬁcant difference in terms of predominant bacterial
pathogen or treatment.
Conclusion: ED was isolated in 5.8% of patients without lung transplant
(9% >12 y). Aspergillus fumigatus colonization and genotype seem to be predis-
posing factors.
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Scedosporium (S) spp. are associated with poor outcome in immunocompromised
patients due to low susceptibility to conventional antifungal (AF) drugs. Azole
arsenal recently provided 2 active drugs voriconazole (VRZ), posaconazole (PSZ).
We present our experience in managing CFLT with S colonisation over the past
10 years.
All CFLT S+ were recorded with mycology, clinical outcome, immunosuppres-
sants (IS) and AF data; S was assessed by direct examination on respiratory
samples, speciﬁc cultures, morphologic identiﬁcation, AF susceptibility (Etest®).
Therapeutic drug monitoring (TDM) of both azole and IS were routinely performed
using analytical methods.
Out of 122 CFLT (2000−09), we observed n = 7 S (7 S. apiospermum +1 S. proliﬁ-
cans), 5/7 before T, pre-treated with classical susceptibility (VRZ, PSZ) of isolates.
Demographics − 19.9±4.4 yrs, 48.4±9.3 kg, 4M/3F − ﬁtted our usual CFLT.
LT surgery exposed to bronchial stenosis.
AF was introduced de novo (except 1 at S+) as VRZ (6) or PSZ (1);VRZ stopped
(n = 3), 1 after 1 yr without relapse, 1 for photosensitisation with S fungal ball,
ablation and PSZ, 1 for resistance and PSZ. Mean VRZ and PSZ maintenance doses
were respectively 572±207 and 1550±638mg/d with 1.4±0.7 and 0.8±0.6mg/L;
IS treatment were steroids, tacrolimus and adjuvants. Survival ranged from 12 to
102mths after T, 2 died (BOS), 5 ongoing.
S colonisation may be controlled in CFLT, using de novo probably lifelong VRZ
or PSZ. VRZ de novo is more appropriate if IV, but exposes to photosensitisation
(n = 3) (skin protection) and neuropathy (n = 1). Azole PK variability in CF need
higher dosage, long time to steady-state and careful TDM to achieve compliance
with safe DDI management.
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Introduction: The Scedosporium apiospermum is the second most frequent ﬁla-
mentous fungus that can be found in patients with CF after Aspergillus fumigatus.
Filamentous fungi may contribute to the local inﬂammatory response and under
special circumstances could be pathogenic and invasive.
Aim: The incidence of colonization by Scedosporium apiospermum in CF patients
and its association with several clinical characteristics.
Population and Method: All 416 CF patients of our department (206 boys,
210 girls, mean age: 13.9 years) were surveyed for colonization with Scedosporium
apiospermum during the last 3 years. Sputum cultures collected during their routine
clinical visits or on admission to the hospital were inoculated on yeast exctract-
peptone-dextrose agar plates. The colonization was associated with several clinical
factors: the age of the patients, pancreatic function, chronic colonization with
pseudomonas aeruginosa, chronic use of inhaled antibiotics, prolonged use of
inhaled and systematic steroids.
Results: The incidence of Scedosporium apiospermum in our CF population was
2%. The mean age of the patients at the age of ﬁrst colonization was 17.6 years.
There was a strongly positive relation with chronic use of inhaled antibiotics
(p< 0.001) and systematic steroids (p< 0.001). Colonization with Scedosporium
apiospermum was not associated with any deterioration in patients’ clinical condi-
tion, apart from one child, who developed signs of infection.
Conclusion: The intensiﬁcation of therapy in CF patients with antibiotics and
steroids may facilitate the colonization by Scedosporium apiospermum, so mon-
itoring with suitable fungal culture methods is mandatory.
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Scedosporium apiospermum (S.a) is an emerging ﬁlamentous fungus described
as one of the major fungal agents responsible for chronic airway colonisation
in cystic ﬁbrosis (CF) patients. Although the signiﬁcance of patients’ respiratory
tract colonisation by S.a is still unclear, this fungus may contribute to the local
inﬂammatory response, and therefore to the progressive deterioration of lung
function. We studied S.a seroprevalence in a large prospective cohort of CF patients
and compared the clinical features of seropositive and seronegative patients. Serum
samples from 395 CF patients were analysed retrospectively. Total antibodies against
S.a were determined by ELISA using cytosolic antigens extracted by mechanical
disruption. Patients’ demographic and clinical data were obtained by a systematic
review of medical records and univariate analysis was performed to compare
the clinical characteristics of seropositive and seronegative patients. Antibodies
against S.a were detected in 98 patients (24.1%), the median age of seropositive
patients was 20.5 years [1.7−53 years]. The prevalence of immunisation against
S.a regularly increased with age and reached 46% in patients older than 35 years.
Results of univariate analysis revealed that seropositivity to S.a was associated with
age, diabetes mellitus, Aspergillus spp airway colonisation and poor pulmonary
function. In conclusion, our results show that an immune response against S.a can
be detected in almost one-fourth of cystic ﬁbrosis patients. The clinical relevance of
the immunisation against S.a is unknown and a prospective study will be planned
to evaluate the long-term clinical outcome of seropositive patients.
